Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Viatris (NASDAQ: VTRS) announced positive Phase 3 study results for its investigational XULANE LO™ low dose contraceptive patch. The study, involving 1,272 women across 81 sites in the U.S., Puerto Rico, and Canada, demonstrated favorable efficacy with a Pearl Index of 4.14 and a 3.7% cumulative pregnancy probability over 13 cycles.
The patch showed strong performance metrics, including excellent adhesion with only 1.3% of patches completely detaching during the seven-day wearing period and less than 1% of subjects reporting severe local application site reactions. Most treatment emergent adverse events were mild-to-moderate, with favorable cycle control and low unscheduled bleeding events. Viatris plans to submit a New Drug Application to the FDA in the second half of 2025.
Viatris (NASDAQ: VTRS) has announced a quarterly dividend payment of $0.12 per share for its common stock shareholders. The dividend was declared by the company's Board of Directors on May 5, 2025. Shareholders who own VTRS stock as of the close of business on May 23, 2025 (record date) will receive the dividend payment on June 16, 2025.
Viatris (NASDAQ: VTRS) has announced significant changes to its Board of Directors. Frank D'Amelio, former Pfizer CFO, and Dr. Michael Severino, current CEO of Tessera Therapeutics, have been appointed as new board members. Meanwhile, current directors Rajiv Malik and Harry Korman will retire at the end of their terms in December 2025.
D'Amelio brings 20 years of experience as a public company CFO, including 15 years at Pfizer where he managed corporate finance functions and global supply. Severino's background includes serving as Vice Chairman and President of AbbVie, where he also held roles as EVP of R&D and Chief Scientific Officer. He previously spent 10 years at Amgen in various leadership positions.
The appointments are part of Viatris' ongoing Board refreshment efforts aimed at accelerating shareholder return and positioning the company for long-term growth.
Viatris (Nasdaq: VTRS), a global healthcare company, has announced its participation in the BofA Securities 2025 Healthcare Conference in Las Vegas. The presentation is scheduled for Tuesday, May 13, 2025, at 5 p.m. PT / 8 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through investor.viatris.com. An archived version will also be available for -time viewing at the same location following the live event.
Viatris (VTRS) has filed supplemental New Drug Applications with Japan's Ministry of Health, Labor and Welfare for EFFEXOR® to treat adults with generalized anxiety disorder (GAD). The application follows successful Phase 3 trials where the drug demonstrated superiority over placebo in anxiolytic effects, meeting all seven secondary efficacy endpoints.
The filing aims to introduce the first approved GAD treatment option in Japan, where an estimated 2.6% of the population experiences GAD in their lifetime, with recent studies suggesting a prevalence rate of 7.6%. EFFEXOR®, a serotonin-noradrenaline reuptake inhibitor (SNRI), is already approved for major depressive disorder in Japan and for GAD treatment in over 80 countries globally.
Viatris Inc. (VTRS) has appointed Hemanth J. Varghese as Chief Strategy Officer, joining the Company's Executive Leadership Team. Varghese brings over 20 years of experience in strategy, operations, and corporate development within healthcare companies.
Prior to this appointment, Varghese served as President and COO at Venus Concept, SVP of Strategy & Operations at HLS Therapeutics, and held executive positions at Endo International, Valeant Pharmaceuticals, and Bausch & Lomb. He holds a bachelor's degree and Ph.D. in medical biophysics from the University of Western Ontario and is a Chartered Financial Analyst.
CEO Scott A. Smith expressed confidence that Varghese's expertise will be important for Viatris's growth strategy in 2026 and beyond.
Viatris (VTRS) has announced a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes. The settlement, which does not admit wrongdoing or liability, requires the company to pay up to $335 million over nine years, with annual payments ranging between $27.5 and $40 million.
The company had previously accounted for this potential settlement in its 2024 Form 10-K. Viatris, which has a minimal presence in the U.S. opioids market, manufactures generic versions of naloxone (overdose reversal drug) and buprenorphine/naloxone (opioid addiction treatment). The company is also developing a novel delivery system for meloxicam, a non-opioid pain medication.